Table 2 Study characteristics
From: Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review
Study | Study design | Participants (intervention/control) | Treatment/index test | Patient-relevant outcomes/ reference test | Location/recruitment period | Weeks’ gestation Median [min; max] | Drop-out (intervention/control) |
|---|---|---|---|---|---|---|---|
Huchet 1987 [29] | prospective intervention study | 1969 (927/955) with RhD-positive newborns: (599/590) | 100 μg anti-D immunoglobulin, one dose at 26 to 29 and one at 32–36 weeks’ gestation | sensitization | 23 hospitals in the Paris region 01/1983–06/1984 |  | Not stated |
Lee 1995 [30] | RCT | 2541 (1268/1273) with RhD-positive newborns: (513/595) | 250 IU anti-D immunoglobulin at 28 and 34 weeks’ gestation | sensitization | Multi-center study in UK Not stated |  | 642 (362/280) |
De Haas 2016 [17] | prospective cohort study | 32,222 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | Netherlands (national screening program) 07/2011–10/2012 | Mean in weeks + days [SD] 27 + 6 [0 + 6] [min; max] [27; 29] | 6433 |
Clausen 2014 [18] | prospective cohort study | 14,547 | cff-DNA RHD Exons 5, 7 or 10 | serologic cord blood testing | Denmark (national screening program) 01/2010 for 2 years | 25 [n. a.] | 1879 |
Haimila 2017 [19] | prospective cohort study | 10,814 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing / heel stick | Finland (national screening program) 02/2014–01/2016 | n. a. [24; 26] | 0 |
Wikman 2012 [20] | prospective cohort study | 4118 | cff-DNA RHD Exon 4 | serologic cord blood testing / blood sample of newborn | Sweden 09/2009–05/2011 | 10 [3; 40] | 466 |
Chitty 2014 [21] | prospective cohort study | 3039 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | England 2009–2012 | 19 [5; 35] | 781 |
Finning 2008 [22] | prospective cohort study | 1997 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | England/not stated | 28 [8; 38] | 128 |
Müller 2008 [5] | prospective cohort study | 1113 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | Germany 2006 – not stated | 25 [6; 32] | 91 |
Macher 2012 [23] | prospective cohort study | 1012 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | Spain 2010 | n.a. [10; 28] | 0 |
Hyland 2017 [24] | prospective cohort study | 665 | cff-DNA RHD Exon 5 and 10 | serologic cord blood testing | Australia Not stated | 19.3 [9; 37] | 66 |
Akolekar 2011 [26] | prospective cohort study | 591 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | UK Not stated | 12,4 [11; 14] | 5 |
Minon 2008 [27] | prospective cohort study | 563 | cff-DNA RHD Exons 4, 5 and 10 | serologic cord blood testing | Belgium 11/2002–12/2006 | 17,5 [10; 38] | Not stated |
Soothill 2015 [28] | prospective cohort study | 529 | cff-DNA RHD Exons 5 and 7 | serologic cord blood testing | England 04–09/2013 | Not stated | 30 |